Attached files
file | filename |
---|---|
EX-99.2 - PRESS RELEASE, DATED OCTOBER 11, 2018 - ENDRA Life Sciences Inc. | ndra_ex99-2.htm |
EX-99.1 - PRESS RELEASE, DATED OCTOBER 10, 2018 - ENDRA Life Sciences Inc. | ndra_ex99-1.htm |
EX-5.1 - OPINION OF K&L GATES LLP - ENDRA Life Sciences Inc. | ndra_ex5-1.htm |
EX-1.1 - UNDERWRITING AGREEMENT - ENDRA Life Sciences Inc. | ndra_ex1-1.htm |
8-K - CURRENT REPORT - ENDRA Life Sciences Inc. | ndra_8k.htm |
Exhibit 99.3
ENDRA Life Sciences Announces Closing of Public Offering and
Exercise of Over-Allotment Option
ANN ARBOR, Michigan – October 15, 2018 – ENDRA
Life Sciences Inc. (“ENDRA” or the
“Company”) (NASDAQ: NDRA), a developer of enhanced
ultrasound technologies, has closed its previously announced
underwritten public offering of 1,285,000 shares of common stock at
an offering price to the public of $2.10 per share. In connection
with the offering, the underwriter exercised in full its
over-allotment option to purchase an additional 192,750 shares of
common stock at the public offering price to cover over-allotments.
All of the shares of common stock were offered by the
Company.
As a
result, the total public offering size was 1,477,750 shares of
common stock, and the gross proceeds from the public offering were
approximately $3.1 million, before deducting underwriting discounts
and offering expenses.
National
Securities Corporation, a wholly owned subsidiary of National
Holdings Corporation (NASDAQ: NHLD), acted as sole book-running
manager for the offering.
A shelf
registration statement on Form S-3 relating to the shares of common
stock offered was filed with the Securities and Exchange Commission
(the “SEC”) and is effective. The final prospectus
supplement relating to the offering was filed with the SEC on
October 12, 2018. Copies of the final prospectus supplement and the
accompanying base prospectus relating to this offering may be
obtained by request to the offices of National Securities Corporation, Attention:
Marguerite O’Brien, 200 Vesey Street, 25th Floor, New York,
New York 10281, telephone: (212) 417-8227 or by email at
prospectusrequest@nationalsecurities.com;
or on the SEC’s website at http://www.sec.gov.
This announcement shall not constitute an offer to sell or a
solicitation of an offer to buy these securities, nor shall there
be any offer or sale of these securities in any state or
jurisdiction in which such an offer, solicitation or sale would be
unlawful.
About ENDRA Life Sciences Inc.
ENDRA
Life Sciences Inc. ("ENDRA") (NASDAQ: NDRA) is a developer of
enhanced ultrasound technologies. ENDRA is developing a next
generation Thermo-Acoustic Enhanced UltraSound (TAEUS™)
platform to enable clinicians to visualize human tissue
composition, function and temperature in ways previously possible
only with CT and magnetic resonance imaging (“MRI”) -
at a fraction of the cost, and at the point-of-care. ENDRA's first
TAEUS application will focus on the quantification of fat in the
liver, for early detection and monitoring of Non-Alcoholic Fatty
Liver Disease (“NAFLD”). ENDRA's goal is to bring new
capabilities to ultrasound - thereby broadening access to better
healthcare. For more information, please visit
www.endrainc.com.
About Non-Alcoholic Fatty Liver Disease (NAFLD)
NAFLD
is a condition closely associated with obesity, diabetes,
hepatitis-C and certain genetic predispositions in which fat
accumulates in the liver. NAFLD affects over 1 billion people
globally and is estimated to cost the U.S healthcare system over
$100 billion annually. NAFLD is often asymptomatic and if left
untreated, NAFLD can progress to inflammation (NASH), tissue
scarring (fibrosis), cell death (cirrhosis) and liver cancer. By
2025, NAFLD is forecast to be the greatest root cause of liver
transplants. The only tools currently available for diagnosing and
monitoring NAFLD are impractical: expensive MRI or an invasive
surgical biopsy.
Forward-Looking Statements
All statements in this release that are not based on historical
fact are “forward-looking statements.” While management
has based any forward-looking statements included in this release
on its current expectations, the information on which such
expectations were based may change. Forward-looking statements
involve inherent risks and uncertainties which could cause actual
results to differ materially from those in the forward-looking
statements, as a result of various factors including those risks
and uncertainties described in the Risk Factors and in
Management’s Discussion and Analysis of Financial Condition
and Results of Operations sections of our Annual Report on Form
10-K for the year ended December 31, 2017, which can be found on
the SEC’s website at www.sec.gov. We urge you to consider
those risks and uncertainties in evaluating our forward-looking
statements. We caution readers not to place undue reliance upon any
such forward-looking statements, which speak only as of the date
made. Except as otherwise required by the federal securities laws,
we disclaim any obligation or undertaking to publicly release any
updates or revisions to any forward-looking statement contained
herein (or elsewhere) to reflect any change in our expectations
with regard thereto or any change in events, conditions or
circumstances on which any such statement is based.
Company Contact:
David Wells
Chief Financial Officer
(734) 997-0464
investors@endrainc.com
www.endrainc.com
Media & Investor Relations Contact:
MZ North America
Chris Tyson
Managing Director
(949) 491-8235
NDRA@mzgroup.us
www.mzgroup.us